Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523557 | 0.86 | POLB (0.55) | ALDH1A1MEN1KMT2AABCB1NPC1 | |
| SCHEMBL7525705 | 0.84 | HRH3 (0.52) | ALDH1A1MEN1KMT2AMAPTHTT | |
| SCHEMBL3070333 | 0.83 | CYP2D6 (0.58) | ALDH1A1MEN1KMT2AMAPTHTT | |
| SCHEMBL7559747 | 0.80 | PRMT5 (0.46) | ABCB1CYP2D6EPHX2TSHR | |
| SCHEMBL7534159 | 0.79 | KDM4E (0.62) | ALDH1A1MEN1KMT2AMAPTABCB1 | |
| SCHEMBL8610389 | 0.75 | KDM4E (0.57) | ALDH1A1MEN1KMT2AMAPTABCB1 | |
| SCHEMBL7523886 | 0.73 | KMT2A (0.54) | KMT2AABCB1RAB9ACYP2D6TSHR | |
| SCHEMBL15444518 | 0.73 | ALDH1A1 (0.97) | ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL8790177 | 0.72 | ACE2 (0.48) | ALDH1A1MEN1KMT2AABCB1RECQL | |
| SCHEMBL7526130 | 0.72 | ABCB1 (0.49) | ALDH1A1MEN1KMT2AABCB1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | CYTRX CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745465-B2 | Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof | CYTRX CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7148239-B2 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | CYTRX CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-04-08 | — | — | US | disclosed |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-01-29 | — | — | US | disclosed |
| US-6653326-B1 | For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 2003-11-25 | — | — | US | disclosed |
| EP-0801649-B1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-08-07 | — | — | EP | disclosed |
| EP-0832079-B1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-03-27 | — | — | EP | disclosed |
| US-6002002-A | Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 1999-12-14 | — | — | US | disclosed |
| EP-0832079-A1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997000251-A1 | ANTI-ISCHAEMIC HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | BIOREX KUTATO ES FEJLESZTO RT. (HU) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | HSPE1, HSF1, HSP90AB2P | ALDH1A1 533/4885MEN1 4335/4885KMT2A 3924/4885 |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | ALDH1A1 641/4885MEN1 4141/4885KMT2A 3889/4885 |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | ALDH1A1 641/4885MEN1 4141/4885KMT2A 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.